ARMO BioSciences Takes $50M
Redwood City-based ARMO BioSciences, which is developing immunotherapy drugs, announced today that it has raised $50M in a Series C financing. The financing came from Kleiner Perkins Caufield & Byers (KPCB), OrbiMed, DAG Ventures and NanoDimension, plus HBM Healthcare Investments, GV (formerly Google Ventures), Celgene Corporation, Industrial Investors Group and private investment funds advised by Clough Capital Partners L.P. ARMO's products are targeted at the treatment of cancer.
posted on Wednesday, February 10, 2016 (Link to more information)
Related companies:
Armo Biosciences
Related stories:
> ARMO BioSciences Files For IPO
> ARMO BioSciences Adds $67M For Cancer Treatments
> 3-V Biosciences Finds $20M In Funding
> Pacific Biosciences Raises $50M
> Imago Biosciences Sees $26.5M
silicontap.com Home